Latest Market News

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Caterpillar has finalized its acquisition of RPMGlobal, paying shareholders A$5.00 per share and prompting RPMGlobal’s removal from the ASX. This marks a significant shift in the mining software landscape.

Judo Capital Holdings Limited has announced a quarterly distribution of AUD 1.825 per capital note, fully franked and payable on 18 May 2026. The payment reflects a calculated yield based on prevailing market rates and remains subject to company discretion.

BKI Investment Company has finalised its on-market share purchases to satisfy its Dividend Reinvestment Plan obligations, setting the DRP price at $1.74 ahead of the 2026 interim dividend payment.

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.

PhosCo Ltd has raised $5 million through a strongly supported share placement to fund exploration and development at its Gasaat Phosphate Project in Tunisia, positioning the company for upcoming resource milestones.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.